Eye Allergies

Condition

Study comparing the effectiveness of an allergy eye drop to an allergy nasal spray in reducing eye itching associated with allergies.

Study Status

Icon for study status

Currently Enrolling

Study Length

Icon for 5 visits

This study involves up to 5 visits over the course of approximately 5 weeks.

Compensation

If you complete up to 5 visits, you will be compensated up to $450 for your time. If you do not qualify or complete all visits, you may be paid for each visit that you come into the office for.

Current Locations

Icon for current locations

Andover, MA

Upcoming Locations

Icon for upcoming locations

There are no other locations for this study.

General study information

This study is intended for participants who have a history of eye allergies (and a positive reaction to an allergy skin test). Common symptoms of ocular allergies include eye itching, redness, and watering, as well as swollen eyelids and blurred vision. These symptoms can affect one eye or both eyes and can be caused by environmental allergies (IE. Pollen or grass) or year-round allergies (IE. Pet dander or dust).

This study will be evaluating the effectiveness of Pataday® Once Daily Relief Extra Strength eye drop compared to Flonase® Allergy Relief nasal spray in reducing eye itching associated with allergies. Both the eye drop, and nasal spray are already approved by the United States Food and Drug Administration (FDA).

Contact us and see if this study is right for you

Key requirements

Key Inclusion Criteria

  • Must be 18 years or older
  • History of eye allergies
  • Positive allergy skin test within 24 months – Allergy skin tests will be provided at the initial visit.

Key Exclusion Criteria

  • Pregnancy, nursing, or planning a pregnancy
  • Involvement in an investigational study in the last 30 days
  • Unable to discontinue certain medications (will be discussed with you)

Email moving fast icon

Receive Trial Alerts

Sign up for email alerts when new trials and locations are added for a medical condition.